Compare IVT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVT | ADPT |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2005 | 2019 |
| Metric | IVT | ADPT |
|---|---|---|
| Price | $34.82 | $17.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $32.50 | $17.78 |
| AVG Volume (30 Days) | 658.8K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 647.37 | 63.89 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $299,169,000.00 | $276,976,000.00 |
| Revenue This Year | $8.42 | $3.98 |
| Revenue Next Year | $5.25 | $22.72 |
| P/E Ratio | $495.43 | ★ N/A |
| Revenue Growth | 9.20 | ★ 54.77 |
| 52 Week Low | $26.52 | $9.96 |
| 52 Week High | $34.91 | $20.76 |
| Indicator | IVT | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 72.31 | 66.43 |
| Support Level | $30.42 | $14.87 |
| Resistance Level | N/A | $17.52 |
| Average True Range (ATR) | 0.71 | 0.93 |
| MACD | 0.21 | 0.33 |
| Stochastic Oscillator | 83.54 | 81.33 |
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.